Table 6. Patients´ baseline characteristics of treated with 223Ra in the 3 lines of therapy.
| 223Ra therapy | First line (11p) | Concomitant (Abiraterone/Enzalutamide) (13p) | Followed by other treatments (19p) | |
|---|---|---|---|---|
|
| ||||
| Baseline variable | n | n | n | |
| Age | Mean | 70 years | 71 years | 71 years |
| ECOG status | 1 | 3 | 2 | 3 |
| ≥2 | 8 | 11 | 16 | |
| CPL | 1-2 | 8 | 2 | 8 |
| 3 | 3 | 11 | 11 | |
| Bone metastases (Bone-Scan) | 2-6 | 6 | 4 | 5 |
| >6 | 5 | 7 | 10 | |
| Superscan | 0 | 2 | 4 | |
| Hb (g/dL) | <12.9 | 4 | 10 | 11 |
| >13 | 7 | 3 | 8 | |
| PSA (ng/mL) | <99.9 | 10 | 7 | 7 |
| >100 | 1 | 6 | 12 | |
| ALP (U/L) | <199.9 | 6 | 5 | 12 |
| >200 | 5 | 8 | 7 | |